UAE adopts national genomics plan with smart research environment


The Emirates Genome Council has adopted the comprehensive National Genomics Plan for 2026 to 2028, chaired by H.H. Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, to transition toward preventive care and personalized medicine. The initiative aims to provide customized health reports to approximately 900,000 participants starting December 2026 and to foster a reliable, AI-powered research environment.
The 2026–2028 National Genomics Plan in the United Arab Emirates connects a million-strong database with a trusted, AI-powered research environment to advance precision medicine and newborn screening under strict privacy governance.
On November 10, 2026, the Emirates Genome Council adopted the comprehensive National Genomics Plan in the United Arab Emirates for 2026–2028, announcing the transition of the large-scale national program into advanced implementation phases that include preventive healthcare, specialized scientific research, and the issuance of personalized health reports for participants. This announcement followed an official meeting chaired by H.H. Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, as reported by the Emirates News Agency (WAM) in its official report.
According to official data released by the agency, the Emirati Genome Program has successfully reached nearly 1 million participants, and officials plan to provide customized genetic health reports to approximately 900,000 participants starting in December 2026. Although a secondary report indicated a different timeframe for the plan, the official WAM statement explicitly specifies the period from 2026 to 2028 as the officially approved timeline.
The project explicitly connects to artificial intelligence technologies, though characterizing this connection requires high scientific and methodological precision. The comprehensive plan includes enhancing and developing the “trusted research environment,” a secure computing infrastructure that supports the analysis of genomic and health information using advanced computational methods, most notably artificial intelligence algorithms.
This specialized computing environment aims to enable authorized researchers to investigate complex genetic patterns and explore potential applications in the field of precision medicine. Therefore, it is neither a new consumer chatbot nor a claim that artificial intelligence alone and independently can diagnose all conditions and genetic diseases.
The planned personal health reports include detailed information concerning approximately 214 genetic conditions and health traits. Concurrently, the expanded newborn screening program addresses more than 730 genes linked to over 815 childhood genetic conditions that are amenable to early therapeutic intervention or proactive, effective care.
These detailed figures reflect specifications and targets approved within the national program, and do not mean that all planned reports have already been delivered to participants today, nor do they imply that every genetic test automatically leads to a definitive, final medical diagnosis without clinical follow-up.
Genomic interpretation processes can detect genetic variants associated with increased probabilities of developing certain conditions. However, the presence of a genetic predisposition does not equate to the inevitable certainty that an individual will actually develop the disease in the future, as a genetic result may require additional clinical confirmation, specialized genetic counseling sessions, or supplementary medical tests.
Furthermore, artificial intelligence-based models in genomics require rigorous scientific validation across the actual populations to which they will be applied, taking into consideration the challenges of rare genetic variants and missing data to avoid inaccurate conclusions.
Privacy considerations and institutional governance occupy a primary position in this project. Genomic information is extremely sensitive because it can reveal health and genetic characteristics that extend beyond the individual participant to include their biological relatives as well. Consequently, the trusted research environment requires stringent access controls, full auditability and reviewability, and explicit rules governing any secondary research uses.
WAM reported that 21 research and health entities have been invited to participate in the initiative, with the caveat that issuing invitations does not mean research studies are already completed. Future evidence will be represented by the delivery of actual reports, achieved research results, privacy guarantees, and improvements in patient health outcomes.
Question: What are the most prominent targets of the 2026–2028 National Genomics Plan in the UAE?
Answer: It aims to transition the Emirati Genome Program—which has reached one million participants—toward preventive and personalized medicine, and to provide customized reports to approximately 900,000 participants starting in December 2026.
Question: How is artificial intelligence employed within the National Genomics Plan?
Answer: It is used by enhancing the trusted research environment, which allows authorized researchers to analyze genomic and health data using advanced computational methods to support precision medicine research.
Question: What do the personal reports and the expanded newborn screening program cover?
Answer: The personal reports cover 214 genetic conditions and health traits, while the newborn screening program tests more than 730 genes associated with over 815 childhood genetic conditions amenable to early intervention.
Question: Why do genetic data require stringent privacy governance and clinical counseling?
Answer: Because genetic predisposition does not mean the inevitability of disease; rather, it requires medical confirmation and genetic counseling. Additionally, genetic fingerprints reveal sensitive information concerning both the individual and their relatives.